re your first para, doesn't track with how mgmt have behaved in the past wrt comms on trials slipping, so I can't find much credence there myself.
But I like your thought re removing the double up of the checkvacc trial, thanks. Although I would say the results and progress v cost likely played into their decision making as well.
Fingers crossed for the TNBC patients on the vaxinia trial.
GLTA.
IMU Price at posting:
8.7¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)